<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01912677</url>
  </required_header>
  <id_info>
    <org_study_id>4000</org_study_id>
    <nct_id>NCT01912677</nct_id>
  </id_info>
  <brief_title>Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy</brief_title>
  <official_title>Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Government Medical College, Nagpur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daga Memorial Women's Hospital, Nagpur, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pragmatic, open-label, randomised control trial of three oral anti-hypertensive
      regimens for women with severe hypertension in pregnancy. Women presenting with severe
      hypertension in pregnancy in two hospitals in Nagpur, India will be randomised to one of
      three oral regimens: nifedipine, labetalol or methyldopa. This trial will compare the
      efficacy, safety and side effects of these three oral regimens for management of hypertension
      in pregnant women. The investigators hypothesize that nifedipine treatment of severe
      hypertensive parturient women is more effective than treatment with labetalol or methyldopa
      in controlling high blood pressure within six hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pragmatic, open-label, randomised control trial of three oral anti-hypertensive
      regimens for women with severe hypertension in pregnancy. Women presenting with severe
      hypertension in pregnancy in two hospitals in Nagpur, India will be randomised to one of
      three oral regimens: nifedipine, labetalol or methyldopa. This trial will compare the
      efficacy, safety and side effects of these three oral regimens for management of hypertension
      in pregnant women. The investigators hypothesize that nifedipine treatment of severe
      hypertensive parturient women is more effective than treatment with labetalol or methyldopa
      in controlling high blood pressure within six hours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful outcome</measure>
    <time_frame>6 hours</time_frame>
    <description>Successful outcome will be considered blood pressure that reaches the target (defined as 120-150mmHg systolic and 70-100 mmHg mm Hg diastolic) at 6h without an adverse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of hourly BP's in severe range</measure>
    <time_frame>one hour</time_frame>
    <description>the number of hourly BP's in severe range</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">894</enrollment>
  <condition>Hypertension in Pregnancy</condition>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive an initial dose of oral nifedipine 10mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 10mg dose can be provided each hour for two additional doses (30 mg total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methyldopa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Labetalol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will receive an initial dose of oral labetalol 200mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 200mg dose can be provided each hour for two additional doses (600 mg total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <arm_group_label>Nifedipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol</intervention_name>
    <arm_group_label>Labetalol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyldopa</intervention_name>
    <arm_group_label>Methyldopa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant gestational age &gt;= 28 weeks

          -  Systolic blood pressure &gt;=160 mm Hg OR a diastolic blood pressure of &gt;=110 mm Hg
             measured twice more than 15 minutes apart

          -  Able to swallow pills

          -  &gt;= 18 years

        Exclusion Criteria:

          -  Indication for emergent cesarean or known fetal anomaly

          -  Anti-hypertensive therapy received in the past 12 hours

          -  History of eclampsia or other adverse CNS complication (e.g., stroke or PRES) in this
             pregnancy

          -  Actively wheezing at time of enrollment or history of asthma complications

          -  Known coronary artery disease or type I DM with microvascular complications or signs
             of heart failure or clinical dissection of the aorta
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hillary Bracken, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hillary Bracken, PhD</last_name>
    <phone>2124481230</phone>
    <email>hbracken@gynuity.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Daga Women's Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaishali Khedikar, MD</last_name>
      <email>srmundle@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vaishali Khedikar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Government Medical College</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuchita Mundle, MD</last_name>
      <email>srmundle@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rajeshree Patil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2013</study_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension in pregnancy</keyword>
  <keyword>preeclampsia</keyword>
  <keyword>anti-hypertension</keyword>
  <keyword>labetalol</keyword>
  <keyword>nifedipine</keyword>
  <keyword>methyldopa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Labetalol</mesh_term>
    <mesh_term>Methyldopa</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

